CN103157084A - Drug for treating osteoporosis - Google Patents
Drug for treating osteoporosis Download PDFInfo
- Publication number
- CN103157084A CN103157084A CN 201310111069 CN201310111069A CN103157084A CN 103157084 A CN103157084 A CN 103157084A CN 201310111069 CN201310111069 CN 201310111069 CN 201310111069 A CN201310111069 A CN 201310111069A CN 103157084 A CN103157084 A CN 103157084A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- radix
- fructus
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a drug for treating osteoporosis. The drug is prepared from the following materials in parts by weight: 5-10 parts of radix scrophulariae, 10-20 parts of rhizoma zingiberis, 20-30 parts of dogwood, 10-20 parts of platycodon grandiflorum, 15-25 parts of radix angelicae, 5-15 parts of inula flower, 10-30 parts of cowherb seed, 1-15 parts of herba aristolochiae, 10-20 parts of radices sileris, 15-30 parts of oriental wormwood, 20-30 parts of radix rehmanniae preparata, 1-20 parts of morinda officinalis, 1-20 parts of celandine, 10-25 parts of lalang grass rhizome, 10-30 parts of cocklebur fruit, 1-20 parts of emblic leafflower fruit, 15-20 parts of kamuning, 10-20 parts of kaladana, 10-20 parts of herba inulae, 15-30 parts of glabrous sarcandra herb, 10-20 parts of clinopodium polycephalum, 10-25 parts of cassia twig, 5-15 parts of nelumbium speciosum, 1-20 parts of uniflower swisscentaury root, 15-25 parts of rhododendron dauricum, 15-25 parts of potentilla discolor, 10-20 parts of calyx seu fructus physalis, 15-25 parts of radix bupleuri, 10-20 parts of corydalis amabilis, 15-25 parts of cortex mori radicis, 20-30 parts of lindley eupatorium, 1-20 parts of gorgon fruit and 10-25 parts of chinese azalea flower. All the components of the drug for treating osteoporosis in the invention are natural materials, so the drug is good in safety, clear in curative effect and suitable for large-scale promotion clinically.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of osteoporotic medicament for the treatment of.
Background technology
Osteoporosis is one group of osteopathia that many reasons causes, osseous tissue has normal calcification, and calcium salt and substrate are normal ratio, and the metabolic osteopathy that is reduced to characteristics with unit volume internal skeleton tissue mass becomes.In most osteoporosises, due to the minimizing of osseous tissue increases mainly due to bone absorption.Morbidity is how slowly indivedual very fast, take skeleton pain, be easy to fracture as feature biochemical analysis normal.The visible cortical bone of pathological anatomy is poor, and the sparse atrophy osteoid of bone trabecula layer is not thick.
Summary of the invention
The purpose of this invention is to provide a kind of osteoporotic medicament for the treatment of.
in order to realize purpose of the present invention, the invention provides a kind of osteoporotic medicament for the treatment of, it is to be made by the material of following weight proportioning: Radix Scrophulariae 5-10 part, Rhizoma Zingiberis 10-20 part, Fructus Corni 20-30 part, Radix Platycodonis 10-20 part, Radix Angelicae Dahuricae 15-25 part, Flos Inulae 5-15 part, Semen Vaccariae 10-30 part, Herba Aristolochiae 1-15 part, Radix Saposhnikoviae 10-20 part, Herba Artemisiae Scopariae 15-30 part, Fructus Terminaliae Billericae 20-30 part, Radix Morindae Officinalis 1-20 part, Herba Chelidonii 1-20 part, Rhizoma Imperatae 10-25 part, Fructus Xanthii 10-30 part, Fructus Phyllanthi 1-20 part, Folium Et Cacumen Murrayae 15-20 part, Semen Pharbitidis 10-20 part, Herba Inulae 15-20 part, Herba Sarcandrae 15-30 part, Herba Clinopodii 10-20 part, Ramulus Cinnamomi 10-25 part, Radix seu Herba Gei aleppici 5-15 part, Radix Rhapontici 1-20 part, Folium Rhododendri Daurici 15-25 part, Radix Bupleuri 15-25 part, Rhizoma Corydalis Decumbentis 10-20 part, Cortex Mori 15-25 part, Herba Eupatorii Lindleyani 20-30 part, Semen Euryales 1-20 part and Flos Rhododendri Mollis 10-25 part.
preferably, the osteoporotic medicament for the treatment of of the present invention is to be made by the material of following weight proportioning: 7 parts of Radix Scrophulariaes, 13 parts of Rhizoma Zingiberiss, 22 parts of Fructus Corni, 15 parts of Radix Platycodoniss, 21 parts of the Radixs Angelicae Dahuricae, 13 parts of Flos Inulaes, 28 parts of Semen Vaccariae, 11 parts of Herba Aristolochiaes, 17 parts of Radix Saposhnikoviaes, 24 parts of Herba Artemisiae Scopariaes, 27 parts of Fructus Terminaliae Billericaees, 18 parts of Radix Morindae Officinaliss, 17 parts of Herba Chelidoniis, 23 parts of Rhizoma Imperataes, 21 parts of Fructus Xanthii, 16 parts of Fructus Phyllanthis, 16 parts of Folium Et Cacumen Murrayae, 17 parts of Semen Pharbitidiss, 19 parts of Herba Inulae, 15 parts of Herba Sarcandraes, 14 parts of Herba Clinopodii, 21 parts of Ramulus Cinnamomi, 11 parts of Radix seu Herba Gei aleppici, 13 parts of Radix Rhapontici, 23 parts of Folium Rhododendri Daurici, 24 parts of Radix Bupleuri, 14 parts of Rhizoma Corydalis Decumbentiss, 25 parts of Cortex Mori, 26 parts of Herba Eupatorii Lindleyanis, 24 parts of 16 parts of Semen Euryaless and Flos Rhododendri Mollis.
More preferably, described medicament can be tablet, dispersible tablet, capsule or decoction.
Whole compositions of the osteoporotic medicament for the treatment of of the present invention are all natural materials, and safety is better, and curative effect is clear and definite, are suitable for large-scale promotion clinically.
The specific embodiment
Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for explanation the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, otherwise the percent in the present invention is percetage by weight.
Embodiment decoction of the present invention
take Radix Scrophulariae 7 grams, Rhizoma Zingiberis 13 grams, Fructus Corni 22 grams, Radix Platycodonis 15 grams, the Radix Angelicae Dahuricae 21 grams, Flos Inulae 13 grams, Semen Vaccariae 28 grams, Herba Aristolochiae 11 grams, Radix Saposhnikoviae 17 grams, Herba Artemisiae Scopariae 24 grams, Fructus Terminaliae Billericae 27 grams, Radix Morindae Officinalis 18 grams, Herba Chelidonii 17 grams, Rhizoma Imperatae 23 grams, Fructus Xanthii 21 grams, Fructus Phyllanthi 16 grams, Folium Et Cacumen Murrayae 16 grams, Semen Pharbitidis 17 grams, Herba Inulae 19 grams, Herba Sarcandrae 15 grams, Herba Clinopodii 14 grams, Ramulus Cinnamomi 21 grams, Radix seu Herba Gei aleppici 11 grams, Radix Rhapontici 13 grams, Folium Rhododendri Daurici 23 grams, Radix Bupleuri 24 grams, Rhizoma Corydalis Decumbentis 14 grams, Cortex Mori 25 grams, Herba Eupatorii Lindleyani 26 grams, Semen Euryales 16 grams and Flos Rhododendri Mollis 24 grams, add 2000 milliliters of entry, in being housed, heated 4 hours under 80 ℃ by the flask of condensing tube, filter.Filtrate is concentrated into 600 milliliters, namely gets decoction of the present invention.
Experimental example
One, patient's data
1.2.1 diagnostic criteria is with reference to " Chinese's osteoporosis suggestion diagnostic criteria (the second original text) ", must possess whole body pain, be that obviously microtrauma can cause fracture mainly with lumbar and back pain, or the scheuermann kyphosis deformity, or bone density (BMD) reduces by 2 above persons of standard deviation.
1.2.2 1. inclusive criteria has typical OP clinical symptoms, meets the OP diagnostic criteria; 2. the age is 45-70 person between year; 3. voluntarily as study subject, signature Informed Consent Form, and energy reception test pharmaceutical dosage form guarantee to complete person's course for the treatment of.
1.2.3 1. exclusion standard has secondary osteoporosis and other serious complication persons such as hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma; 2. present obvious bow-backed deformity, deformity and disability person; 3. suffers from the severe cardiac cerebrovascular, liver, kidney, lung and hemopoietic system primary disease person; 4. within the observation period course for the treatment of, due to a variety of causes, as go out, residence migration etc. can not obtain the person of following up a case by regular visits on request; 5. to this drug allergy person or to the multi-medicament allergy sufferers; 6. psychosis or patients with Alzheimer disease; 7. duration of test is failed medication or the person of dropping by the wayside in accordance with regulations.
Choose patient's 50 examples according to above-mentioned standard, male 25 examples wherein, female's 25 examples, 50 years old mean age.
Two, Therapeutic Method
Use the decoction for preparing in embodiment to treat, every day 2 times, each oral 50 milliliters.Take 30 days as a course for the treatment of, carry out continuously two courses for the treatment of.
Three, criterion of therapeutical effect
According to the Zheng Xiao cornel. new Chinese medicine guideline of clinical investigations (trying) (s) Beijing: Chinese Medicine science and technology publishing house, 2002; 357-358. formulate criterion of therapeutical effect.Produce effects: pain disappears fully, and BMD checks and shows that bone density increases; Effectively: pain is obviously alleviated, and BMD checks that having no bone density descends; Invalid: relatively front with treatment, each side is all without improving.
Four, result
50 routine patients all meet the produce effects standard after treatment.
Claims (3)
1. treat osteoporotic medicament for one kind, it is characterized in that, it is to be made by the material of following weight proportioning: Radix Scrophulariae 5-10 part, Rhizoma Zingiberis 10-20 part, Fructus Corni 20-30 part, Radix Platycodonis 10-20 part, Radix Angelicae Dahuricae 15-25 part, Flos Inulae 5-15 part, Semen Vaccariae 10-30 part, Herba Aristolochiae 1-15 part, Radix Saposhnikoviae 10-20 part, Herba Artemisiae Scopariae 15-30 part, Fructus Terminaliae Billericae 20-30 part, Radix Morindae Officinalis 1-20 part, Herba Chelidonii 1-20 part, Rhizoma Imperatae 10-25 part, Fructus Xanthii 10-30 part, Fructus Phyllanthi 1-20 part, Folium Et Cacumen Murrayae 15-20 part, Semen Pharbitidis 10-20 part, Herba Inulae 15-20 part, Herba Sarcandrae 15-30 part, Herba Clinopodii 10-20 part, Ramulus Cinnamomi 10-25 part, Radix seu Herba Gei aleppici 5-15 part, Radix Rhapontici 1-20 part, Folium Rhododendri Daurici 15-25 part, Radix Bupleuri 15-25 part, Rhizoma Corydalis Decumbentis 10-20 part, Cortex Mori 15-25 part, Herba Eupatorii Lindleyani 20-30 part, Semen Euryales 1-20 part and Flos Rhododendri Mollis 10-25 part.
2. the osteoporotic medicament for the treatment of according to claim 1, it is characterized in that, it is to be made by the material of following weight proportioning: 7 parts of Radix Scrophulariaes, 13 parts of Rhizoma Zingiberiss, 22 parts of Fructus Corni, 15 parts of Radix Platycodoniss, 21 parts of the Radixs Angelicae Dahuricae, 13 parts of Flos Inulaes, 28 parts of Semen Vaccariae, 11 parts of Herba Aristolochiaes, 17 parts of Radix Saposhnikoviaes, 24 parts of Herba Artemisiae Scopariaes, 27 parts of Fructus Terminaliae Billericaees, 18 parts of Radix Morindae Officinaliss, 17 parts of Herba Chelidoniis, 23 parts of Rhizoma Imperataes, 21 parts of Fructus Xanthii, 16 parts of Fructus Phyllanthis, 16 parts of Folium Et Cacumen Murrayae, 17 parts of Semen Pharbitidiss, 19 parts of Herba Inulae, 15 parts of Herba Sarcandraes, 14 parts of Herba Clinopodii, 21 parts of Ramulus Cinnamomi, 11 parts of Radix seu Herba Gei aleppici, 13 parts of Radix Rhapontici, 23 parts of Folium Rhododendri Daurici, 24 parts of Radix Bupleuri, 14 parts of Rhizoma Corydalis Decumbentiss, 25 parts of Cortex Mori, 26 parts of Herba Eupatorii Lindleyanis, 24 parts of 16 parts of Semen Euryaless and Flos Rhododendri Mollis.
3. the osteoporotic medicament for the treatment of according to claim 1, is characterized in that, described medicament can be tablet, dispersible tablet, capsule or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310111069 CN103157084A (en) | 2013-03-22 | 2013-03-22 | Drug for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310111069 CN103157084A (en) | 2013-03-22 | 2013-03-22 | Drug for treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103157084A true CN103157084A (en) | 2013-06-19 |
Family
ID=48580949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310111069 Pending CN103157084A (en) | 2013-03-22 | 2013-03-22 | Drug for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103157084A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103461805A (en) * | 2013-08-18 | 2013-12-25 | 青岛福加德面粉有限公司 | Flour for osteoporosis patients to eat |
| CN103520297A (en) * | 2013-10-08 | 2014-01-22 | 广州加原医药科技有限公司 | Traditional Chinese medicine composition capable of enhancing bone density and preparation method thereof |
-
2013
- 2013-03-22 CN CN 201310111069 patent/CN103157084A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103461805A (en) * | 2013-08-18 | 2013-12-25 | 青岛福加德面粉有限公司 | Flour for osteoporosis patients to eat |
| CN103461805B (en) * | 2013-08-18 | 2014-07-16 | 青岛福加德面粉有限公司 | Flour for osteoporosis patients to eat |
| CN103520297A (en) * | 2013-10-08 | 2014-01-22 | 广州加原医药科技有限公司 | Traditional Chinese medicine composition capable of enhancing bone density and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103157087A (en) | Drug for treating femoral head necrosis | |
| CN103223153B (en) | Medicament for treating femoral head necrosis | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN101703662B (en) | Oral Chinese medicament for treating hyperosteogeny | |
| CN103142982A (en) | Medicine for treating acute upper respiratory infection | |
| CN101897879A (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN103142959A (en) | Medicament for treating urticaria | |
| CN103463295A (en) | Traditional Chinese medicine composite for treating neurodermatitis and preparation method thereof | |
| CN101199653A (en) | Medicament for treating rheumatism | |
| CN103157084A (en) | Drug for treating osteoporosis | |
| CN103301368B (en) | Medicament for treating hyperactivity | |
| CN103142974B (en) | Medicament for treating anxiety disorder | |
| CN102657751B (en) | Medicament for treating osteoporosis | |
| CN102327408B (en) | Medicament for treating osteoporosis | |
| CN101708300A (en) | Medicinal composition for treating scrofula, hyperplasia of mammary glands and benign lymphadenoma | |
| CN101284108A (en) | Traditional Chinese medicine combination for curing lumbar disease | |
| CN103735830A (en) | Traditional Chinese medicine composition for treating osteoporosis | |
| CN103948878A (en) | Traditional Chinese medicinal composition for treating bone diseases | |
| CN104162105A (en) | Medicine for treating acute mastitis | |
| CN103007236B (en) | Chinese medicinal composition for treating ankylosing spondylitis | |
| CN103285108B (en) | Chinese medicinal composition treating lumbago | |
| CN101843718B (en) | Chinese medicament for treating lupus erythematosus | |
| CN105535878A (en) | Compound medicine for treating Raynaud's syndrome | |
| CN103142977A (en) | Medicament for treating dysmenorrhea | |
| CN103142984B (en) | Medicine for treating rheumatism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130619 |